跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
陳 彩雲
教授
內科學科
內科部
電子郵件
teresa
mail.ncku.edu
tw
h-index
2693
引文
26
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1993 …
2026
每年研究成果
概覽
指紋
網路
專案
(1)
研究成果
(120)
類似的個人檔案
(6)
監製作品
(1)
指紋
查看啟用 Tsai-Yun Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Chronic Myelogenous Leukemia
100%
Diffuse Large B-Cell Lymphoma
93%
Infection
70%
T Cell
68%
Imatinib
66%
Myelodysplastic Syndrome
66%
Aplastic Anemia
66%
Cutaneous Lymphoma
66%
Overall Survival
65%
Anaplastic Large Cell Lymphoma
58%
Progression Free Survival
51%
B-Cell Lymphoma
51%
Diseases
45%
Clinical Feature
42%
Peripheral T-Cell Lymphoma
41%
Deferasirox
40%
Autologous Stem Cell Transplantation
39%
NK T Cell Lymphoma
36%
Thrombosis
33%
Bullous Pemphigoid
33%
Polycythemia vera
33%
Von Willebrand Factor Cleaving Proteinase
33%
Dasatinib
33%
Nilotinib
33%
Haemophilia A
33%
Glycoprotein VI
33%
Immunotherapy
33%
Idiopathic Thrombocytopenic Purpura
33%
Eltrombopag
33%
Consolidation Chemotherapy
33%
Lymphocyte
33%
Malignant Neoplasm
33%
Multiple Myeloma
33%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
Programmed Death 1 Ligand 1
33%
Chelation Therapy
33%
Cutaneous T Cell Lymphoma
33%
Mycobacterium Avium-Intracellulare Infection
33%
Allogeneic Hematopoietic Stem Cell Transplantation
33%
Bone Marrow Metastasis
33%
Aprepitant
33%
Cancer Therapy
33%
Bortezomib
33%
Effusion
33%
Abscess
33%
Ravulizumab
33%
Lymphocyte Antibody
33%
Hepatitis C Antibody
33%
Necrosis
33%
Allogeneic Stem Cell Transplantation
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
NK T Cell Lymphoma
86%
Chemotherapy
85%
Imatinib
66%
Acute Lymphoblastic Leukemia
66%
Multiple Myeloma
66%
Overall Survival
59%
Neoplasm
53%
Thrombocytopenia
50%
Lymphoproliferative Disease
38%
Messenger RNA
38%
Angioimmunoblastic T Cell Lymphoma
38%
Anthracycline
38%
Peripheral T Cell Lymphoma
33%
Lung Disease
33%
Cytarabine
33%
Von Willebrand Factor Cleaving Proteinase
33%
Hepatitis B
33%
Aciclovir
33%
Interferon
33%
5,10 Methylenetetrahydrofolate Reductase (FADH2)
33%
Nilotinib
33%
Cytomegalovirus Infection
33%
Hepatitis B Virus
33%
Dasatinib
33%
Verticillium
33%
Thymocyte Antibody
33%
Oxidoreductase
33%
Glycoprotein VI
33%
Eltrombopag
33%
Bortezomib
33%
Nonhodgkin Lymphoma
33%
Aplastic Anemia
33%
Lung Hemorrhage
33%
Lamivudine
33%
Myeloma
33%
Thrombotic Thrombocytopenic Purpura
33%
Stenotrophomonas maltophilia
33%
Pomalidomide
33%
Antiemetic Agent
33%
Aprepitant
33%
Prevalence
33%
Ravulizumab
33%
Tubulin
33%
Hepatitis C Antibody
33%
Lymphocyte Antibody
33%
Thalidomide
33%
Human Alphaherpesvirus 1
33%
Rituximab
33%
Lung Infarction
33%
Keyphrases
Taiwan
79%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
75%
Diffuse Large B-cell Lymphoma (DLBCL)
70%
Chronic Myeloid Leukemia
66%
Asia
41%
Imatinib Resistance
40%
Imatinib
40%
B-cell Lymphoma
36%
National Cohort Study
33%
Administration Safety
33%
JAK2 mutation
33%
Polycythemia Vera
33%
Exon 12 mutation
33%
PLASMIC Score
33%
Hematopoietic Regeneration
33%
Bone Marrow Niche
33%
CML Cells
33%
Myelodysplastic Syndrome
33%
Cranial Irradiation
33%
Lymphoid Neoplasms
33%
Fungal Pathogens
33%
Myeloid Leukemia Cells
33%
BCR-ABL
33%
Leukapheresis
33%
Hepatosplenic Abscesses
33%
Verticillium
33%
Nasal Natural Killer T-cell Lymphoma
33%
Immune Thrombocytopenic Purpura
33%
Glycoprotein VI
33%
Clinical Specimens
33%
Eltrombopag
33%
United States
33%
Totally Implantable Venous Access Port (TIVAP)
33%
Consolidation Chemotherapy
33%
Multi-targeted Tyrosine Kinase Inhibitors
33%
K562
33%
Aplastic Anemia
33%
Combination Chemotherapy
33%
Moderna
33%
Malignant Pleural Effusion
33%
Follicular Lymphoma
33%
Multilocus Approach
33%
Effusion
33%
Tubulin Polymerization Inhibitors
33%
Iron Chelation Therapy
33%
Secondary Lymphoma
33%
Acutely Ill Patients
33%
Karyotype Abnormalities
33%
Maternal Survival
33%
Cutaneous T-cell Lymphoma
33%
